Michel Ntemgwa

Michel Ntemgwa

Auto-generated profile, based on publicly available information

Michel Ntemgwa

McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2017 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
JAJames A. Ayukekbong
James A. Ayukekbong
MNMichel Ntemgwa
Michel Ntemgwa
AAAndrew N. Atabe
Andrew N. Atabe
The causes of antimicrobial resistance (AMR) in developing countries are complex and may be rooted in practices of health care professionals and patients’ behavior towards the use of antimicrobials as well as supply chains of antimicrobials in the population. Some of these factors may include inappropriate prescription practices, inadequate patient education, limited diagnostic facilities, unauthorized sale of antimicrobials, lack of appropriate functioning drug regulatory mechanisms, and non-human use of antimicrobials such as in animal production. Considering that these factors in developing countries may vary from those in developed countries, intervention efforts in developing countries need to address the context and focus on the root causes specific to this part of the world. Here, we describe these health-seeking behaviors that lead to the threat of AMR and healthcare practices that drive the development of AMR in developing countries and we discuss alternatives for disease prevention as well as other treatment options worth exploring.

1 April 2007 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
BBBluma G. Brenner
Bluma G. Brenner
MRMichel Roger
Michel Roger
JRJean‐Pierre Routy
Jean‐Pierre Routy
DMDaniela Moisi
Daniela Moisi
MNMichel Ntemgwa
Michel Ntemgwa
QGQuebec Primary HIV Infection Study Group
Quebec Primary HIV Infection Study Group
Background. A population-based phylogenetic approach was used to characterize human immunodeficiency virus (HIV)—transmission dynamics in Quebec.Meth

12 June 2006 in AIDS
Verified
Journal Article
Closed access
BBBluma G Brenner
Bluma G Brenner
MOMaureen Oliveira
Maureen Oliveira
FDFlorence Doualla-Bell
Florence Doualla-Bell
DMDaniela D Moisi
Daniela D Moisi
MNMichel Ntemgwa
Michel Ntemgwa
MWMark Wainberg
Mark Wainberg
Background: Genotypic diversity among HIV-1 subtypes and circulating recombinant forms (CRF) may lead to distinct pathways to drug resistance. This study evaluated subtype-related differences in the development of resistance in culture to tenofovir. Methods: Genotyping determined nucleotide diversity among subtypes. Representative subtype B, C, CRF1_AE, CRF2_AG, G, and HIV-2 isolates were selected for resistance to tenofovir, lamivudine and didanosine in cell culture. Phenotypic assays determined the effects of the K65R substitution in reverse transcriptase (RT) on drug susceptibility. Results: Subtype C isolates show unique polymorphisms in RT codons 64 (AAG→AAA), 65 (AAA→AAG), and 66 (AAA→AAG), absent in other subtypes. The K65R mutation (AAG→AGG) arose with tenofovir by week 12 in four subtype C selections. In contrast, no tenofovir resistance arose in four subtype B (> 34–74 weeks), one each of CRF2_AG and G (> 30–33 weeks), and three HIV-2 (> 27–28 weeks) selections. K65R appeared after 55 and 73 weeks in two CRF1_AE selections with tenofovir. In contrast, times to the appearance of M184V with lamivudine pressure (weeks 8–14) did not vary among subtypes. Selective didanosine pressure resulted in the appearance of M184V and L74V after 38 weeks in two of four subtype C selections. The K65R transitions in subtype C and other subtypes (AGG and AGA) conferred similar 6.5–10-fold resistance to tenofovir and five to 25-fold crossresistance to each of abacavir, lamivudine, and didanosine, while not affecting zidovudine susceptibility. Conclusion: Tenofovir -based regimens will need to be carefully monitored in subtype C infections for the possible selection of K65R.

1 September 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
MNMichel L. Ntemgwa
Michel L. Ntemgwa
TTThomas D'AQuin Toni
Thomas D'AQuin Toni
BBBluma G. Brenner
Bluma G. Brenner
RCRicardo J. Camacho
Ricardo J. Camacho
MWMark Wainberg
Mark Wainberg

1 February 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
MNMichel Ntemgwa
Michel Ntemgwa
BBBluma G. Brenner
Bluma G. Brenner
MOMaureen Oliveira
Maureen Oliveira
DMDaniela Moisi
Daniela Moisi
MWMark Wainberg
Mark Wainberg
Human immunodeficiency virus type 2 (HIV-2) contains numerous natural polymorphisms in its protease (PR) gene that are implicated in drug resistance in the case of HIV-1. This study evaluated emergent PR resistance in HIV-2. Three HIV-2 isolates were selected for resistance to amprenavir (APV), nelfinavir (NFV), indinavir (IDV), and tipranavir (TPV) in cell culture. Genotypic analysis determined the time to the appearance of protease inhibitor (PI)-associated mutations compared to HIV-1. Phenotypic drug susceptibility assays were used to determine the levels of drug resistance. Within 10 to 15 weeks of serial passage, three major mutations—I54M, I82F, and L90M—arose in HIV-2 viral cultures exposed to APV, NFV, and IDV, whereas I82L was selected with TPV. After 25 weeks, other cultures had developed I50V and I84V mutations. In contrast, no major PI mutations were selected in HIV-1 over this period except for D30N in the context of NFV selective pressure. The baseline phenotypes of wild-type HIV-2 isolates were in the range observed for HIV-1, except for APV and NFV for which a lower degree of sensitivity was seen. The acquisition of the I54M, I84V, L90M, and L99F mutations resulted in multi-PI-resistant viruses, conferring 10-fold to more than 100-fold resistance. Of note, we observed a 62A/99F mutational motif that conferred high-level resistance to PIs, as well as novel secondary mutations, including 6F, 12A, and 21K. Thus, natural polymorphisms in HIV-2 may facilitate the selection of PI resistance. The increasing incidence of such polymorphisms in drug-naive HIV-1- and HIV-2-infected persons is of concern.

11 February 2009 in Retrovirology
Verified
Journal Article
Open access
PDF file
HXHongtao Xu
Hongtao Xu
JMJorge L Martinez-Cajas
Jorge L Martinez-Cajas
MNMichel L Ntemgwa
Michel L Ntemgwa
DCDimitrios Coutsinos
Dimitrios Coutsinos
FFFernando A Frankel
Fernando A Frankel
MWMark Wainberg
Mark Wainberg
We investigated the effects of mutations K65R and K65R plus M184V on enzymatic function and mechanisms of drug resistance in subtype C reverse transcriptase (RT).